Debiopharm International
在场
Debiopharm International 的所有者是 Debiopharm Group.
Debiopharm Group 拥有 3家子公司，其中包括 Après-demain、Debiopharm International 和 Debiopharm Research & Manufacturing。
他们在：
高管
查看带有其 23 名主要高管的组织结构图
Debiopharm International 搜索最多的简介
- Bertrand Ducrey, Chief Executive Officer
- Thierry Mauvernay, Chairman of the Board
- Manuela Perraudin, Human Resources Director
创建提醒
跟踪 Debiopharm International 的高管变动
药店
Debiopharm Group 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Debiopharm International 的最新新闻稿
- Vulgaroo remporte le 9e Challenge qualité de vie du patient avec un prix de 25’000 francs suisse - Debiopharm
- CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections - Debiopharm
- Debiopharm and WhiteLab Genomics announce a collaboration to advance drug target and design in Oncology - Debiopharm
- Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles - Debiopharm
- Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association - Debiopharm
- Debiopharm & WhiteLab Genomics Announce A Strategic Partnership to Advance Drug Target and Design in Oncology - Debiopharm
- ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-Based Radiopharmaceutical Programs Targeting Solid Tumors - Debiopharm
- Debiopharm pose la première pierre de son nouveau bâtiment pouvant accueillir jusqu'à 300 collaborateurs tout en sortant des énergies fossilles pour une exploitation neutre en CO2 - Debiopharm
- Press Releases - Debiopharm
- First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, A 12-Month Triptorelin Formulation for Children with Central Precocious Puberty - Debiopharm
- View more press releases Close
通过电子邮件
